Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Repinotan Bayer.

Helmi L Lutsep1

  • 1The University of Arizona, Department of Neurology, Tucson 85750, USA. lutseph@ohsu.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|July 26, 2002
PubMed
Summary
This summary is machine-generated.

Repinotan, a 5-HT1A agonist, was investigated for ischemic stroke and traumatic brain injury. Development for depression was discontinued, but trials for stroke and brain injury were advanced, with a potential 2006 launch.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.

The Lancet. Neurology·2023
Same author

Endovascular Therapy for Basilar Artery Occlusion: Among the First to Conceptualize, Last to Prove.

Stroke·2023
Same author

Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2022
Same author

Global Impact of COVID-19 on Stroke Care and IV Thrombolysis.

Neurology·2021
Same author

Global impact of COVID-19 on stroke care.

International journal of stroke : official journal of the International Stroke Society·2021
Same author

Prevalence of Retinal Emboli and Acute Retinal Artery Occlusion in Acute Ischemic Stroke.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2019

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Development

Background:

  • Repinotan, an aminomethylchroman derivative, is a 5-HT1A agonist developed by Bayer.
  • It was initially explored for ischemic stroke, traumatic brain injury, and depression.

Purpose of the Study:

  • To evaluate repinotan as a potential therapeutic agent for ischemic stroke and traumatic brain injury.
  • To assess the market potential and launch timeline for repinotan.

Main Methods:

  • Phase III clinical trials were conducted in Canada and the US for stroke and brain injury.
  • Regulatory filings (NDA) and market launch projections were analyzed.

Main Results:

  • Repinotan completed Phase III trials for ischemic stroke and traumatic brain injury.

Related Experiment Videos

  • Development for the oral formulation for depression was discontinued.
  • Projected launch in Europe and the US in 2006, with peak sales estimates ranging from Euro450 million to US $1000 million.

    • Conclusions:

    • Repinotan showed promise for treating ischemic stroke and traumatic brain injury, advancing through late-stage clinical trials.
    • Despite discontinuation for depression, the drug was nearing market for neurological indications with significant sales potential.